The article discusses that the U.S. Food and Drug Administration granted accelerated approval to lurbi nectedin (Zepzelca™) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. It mentions that the approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.